Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 Aug;11(3):597-613, vii.
doi: 10.1016/j.cld.2007.06.010.

Lipid-lowering agents that cause drug-induced hepatotoxicity

Sidharth S Bhardwaj  1 , Naga Chalasani
Affiliations
Review

Lipid-lowering agents that cause drug-induced hepatotoxicity

Sidharth S Bhardwaj et al. Clin Liver Dis. 2007 Aug.

Abstract

The effort to reduce cardiovascular risk factors, including hyperlipidemia, has led to the increased use of lipid-lowering agents. Hyperlipidemic patients often have underlying fatty liver disease, however, and thus may have elevated and fluctuating liver biochemistries. Therefore, caution should be applied before attributing elevated liver tests to lipid-lowering agents. Data indicate that patients who have chronic liver disease and compensated cirrhosis should not be precluded from receiving statins to treat hyperlipidemia. Several recent studies and expert opinion currently fully endorse statin use in patients who have nonalcoholic fatty liver disease and other chronic liver disease if clinically indicated.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Chemical structures of commonly prescribed lipid-lowering medications with known hepatotoxicity
Chemical structure of commonly available lipid lowering agents (Statins, Fibrates, Ezetimibe, and niacin)
See this image and copyright information in PMC

References

    1. American Heart Association. Cardiovascular disease statistics. 2006. [Accessed January 1, 2007]. Available at: http://www.americanheart.org/presenter.jhtml?identifier=4478.
    1. British Heart Foundation statistics website. CVD mortality in Europe. Mar 312005. [Accessed January 1, 2007]. Available at: http://www.heartstats.org/topic.asp?id=753.
    1. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Jr, Clark LT, Hunninghake DB, et al. Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Journal of the American College of Cardiology. 2004;44(3):720–32. - PubMed
    1. Parra JL, Reddy KR. Hepatotoxicity of hypolipidemic drugs. Clinics in Liver Disease. 2003;7(2):415–33. - PubMed
    1. Chitturi S, George J. Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipidlowering agents, psychotropic drugs. Seminars in Liver Disease. 2002;22(2):169–83. - PubMed

Publication types

MeSH terms